{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:50:06Z","timestamp":1781106606729,"version":"3.54.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02278-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:31:38Z","timestamp":1751365898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bibliometric analysis of programmed cell death and immunogenic cell death in hepatocellular carcinoma immunotherapy: global trends and future directions"],"prefix":"10.1007","volume":"16","author":[{"given":"Shan-Peng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"3","key":"2278_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2278_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616\u201330.","journal-title":"J Hepatol"},{"issue":"4","key":"2278_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/SLA.0000000000003575","volume":"273","author":"G Berardi","year":"2021","unstructured":"Berardi G, Igarashi K, Li CJ, Ozaki T, Mishima K, Nakajima K, Honda M, Wakabayashi G. Parenchymal sparing anatomical liver resections with full laparoscopic approach: description of technique and short-term results. Ann Surg. 2021;273(4):785\u201391.","journal-title":"Ann Surg"},{"issue":"1","key":"2278_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1148\/radiol.2016151807","volume":"282","author":"T Pan","year":"2017","unstructured":"Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, Zhao M. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis. Radiology. 2017;282(1):259\u201370.","journal-title":"Radiology"},{"issue":"4","key":"2278_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep.23485","volume":"51","author":"G Cabibbo","year":"2010","unstructured":"Cabibbo G, Enea M, Attanasio M, Bruix J, Crax\u00ec A, Camm\u00e0 C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274\u201383.","journal-title":"Hepatology"},{"key":"2278_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783236","volume":"12","author":"R Xing","year":"2021","unstructured":"Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12: 783236.","journal-title":"Front Immunol"},{"issue":"10126","key":"2278_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"6","key":"2278_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jhep.2019.08.015","volume":"71","author":"F Tovoli","year":"2019","unstructured":"Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G, Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019;71(6):1175\u201383.","journal-title":"J Hepatol"},{"key":"2278_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100702","volume":"51","author":"M Dal Bo","year":"2020","unstructured":"Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resist Updat. 2020;51: 100702.","journal-title":"Drug Resist Updat"},{"key":"2278_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2278_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691\u2013701.","journal-title":"J Exp Med"},{"key":"2278_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101600","volume":"27","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wen J, Zhang G, Fan W, Tan J, Liu H, Li J. Identification and validation of novel immunogenic cell death- and DNA damage response-related molecular patterns correlated with immune status and prognosis in hepatocellular carcinoma. Transl Oncol. 2023;27: 101600.","journal-title":"Transl Oncol"},{"issue":"2","key":"2278_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W, Xu Z, Yang Y, Weng Q, Zhao Z, et al. Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the Anti-PD-1\/L1 Response. Adv Sci (Weinh). 2023;10(2): e2203973.","journal-title":"Adv Sci (Weinh)"},{"key":"2278_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109689","volume":"184","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang Y, Pan J, Gan L, Xue J. Ferroptosis, necroptosis, and pyroptosis in cancer: crucial cell death types in radiotherapy and post-radiotherapy immune activation. Radiother Oncol. 2023;184: 109689.","journal-title":"Radiother Oncol"},{"key":"2278_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5651","author":"RJ Liu","year":"2024","unstructured":"Liu RJ, Yu XD, Yan SS, Guo ZW, Zao XB, Zhang YS. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: mechanisms and immunologic landscape (Review). Int J Oncol. 2024. https:\/\/doi.org\/10.3892\/ijo.2024.5651.","journal-title":"Int J Oncol"},{"issue":"4","key":"2278_CR16","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/hep.30666","volume":"70","author":"C Hage","year":"2019","unstructured":"Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, P\u00f6schinger T, Kiessling F, Ries CH. Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology. 2019;70(4):1280\u201397.","journal-title":"Hepatology"},{"issue":"17","key":"2278_CR17","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cells11172734","volume":"11","author":"PB Bhosale","year":"2022","unstructured":"Bhosale PB, Abusaliya A, Kim HH, Ha SE, Park MY, Jeong SH, Vetrivel P, Heo JD, Kim JA, Won CK, et al. Apigetrin promotes TNF\u03b1-induced apoptosis, necroptosis, G2\/M phase cell cycle arrest, and ROS generation through inhibition of NF-\u03baB pathway in Hep3B liver cancer cells. Cells. 2022;11(17):2734.","journal-title":"Cells"},{"issue":"12","key":"2278_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2278_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/cancers15041295","volume":"15","author":"ME Davola","year":"2023","unstructured":"Davola ME, Cormier O, Vito A, El-Sayes N, Collins S, Salem O, Revill S, Ask K, Wan Y, Mossman K. Oncolytic BHV-1 Is sufficient to induce immunogenic cell death and synergizes with low-dose chemotherapy to dampen immunosuppressive T regulatory cells. Cancers (Basel). 2023;15(4):1295.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2278_CR20","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/JS9.0000000000002095","volume":"111","author":"J Tian","year":"2024","unstructured":"Tian J, Dong YX, Wang L, Wu YM, Zhao ZY, Che GW. Mapping the evolution of 3D printing in cardio-thoracic diseases: a global bibliometric analysis. Int J Surg. 2024;111(1):1629\u201335.","journal-title":"Int J Surg"},{"issue":"5","key":"2278_CR21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/jrsm.1729","volume":"15","author":"M Gusenbauer","year":"2024","unstructured":"Gusenbauer M. Beyond google scholar, scopus, and web of science: an evaluation of the backward and forward citation coverage of 59 databases\u2019 citation indices. Res Synth Methods. 2024;15(5):802\u201317.","journal-title":"Res Synth Methods"},{"issue":"1","key":"2278_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12672-025-02018-z","volume":"16","author":"CJ Zuo","year":"2025","unstructured":"Zuo CJ, Tian J. Global trends and emerging research in nanotechnology for esophageal cancer: a comprehensive bibliometric analysis. Discov Oncol. 2025;16(1):262.","journal-title":"Discov Oncol"},{"issue":"1","key":"2278_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103697","volume":"24","author":"YX Dong","year":"2025","unstructured":"Dong YX, Zhou SC, Tian J. Advancing understanding of autoimmune disease-related interstitial lung disease (AD-ILD): a global perspective on research focus and future directions. Autoimmun Rev. 2025;24(1): 103697.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2278_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103696","volume":"24","author":"H Bai","year":"2025","unstructured":"Bai H, Tian J. Global research landscape on antiphospholipid syndrome and systemic lupus erythematosus: trends, collaborations, and future directions. Autoimmun Rev. 2025;24(1): 103696.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2278_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103691","volume":"24","author":"H Bai","year":"2025","unstructured":"Bai H, Tian J. Advancing the understanding of autoimmune\/inflammatory syndrome induced by adjuvants (ASIA): global research trends, key themes, and emerging frontiers. Autoimmun Rev. 2025;24(1): 103691.","journal-title":"Autoimmun Rev"},{"issue":"10088","key":"2278_CR26","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"1","key":"2278_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"2278_CR28","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"12","key":"2278_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","volume":"12","author":"J Prieto","year":"2015","unstructured":"Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681\u2013700.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2278_CR30","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.","journal-title":"Nat Rev Dis Primers"},{"issue":"7755","key":"2278_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gij\u00f3n M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270\u20134.","journal-title":"Nature"},{"key":"2278_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216935","volume":"593","author":"F Yao","year":"2024","unstructured":"Yao F, Zhou S, Zhang R, Chen Y, Huang W, Yu K, Yang N, Qian X, Tie X, Xu J, et al. CRISPR\/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma. Cancer Lett. 2024;593: 216935.","journal-title":"Cancer Lett"},{"issue":"1","key":"2278_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.trecan.2021.09.003","volume":"8","author":"J Yan","year":"2022","unstructured":"Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022;8(1):21\u20137.","journal-title":"Trends Cancer"},{"issue":"6","key":"2278_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D'Arcy","year":"2019","unstructured":"D\u2019Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582\u201392.","journal-title":"Cell Biol Int"},{"issue":"4","key":"2278_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"2278_CR36","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961.","journal-title":"Front Immunol"},{"issue":"6","key":"2278_CR37","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.21037\/jgo-20-562","volume":"11","author":"D Sun","year":"2020","unstructured":"Sun D, Ma J, Wang J, Wang L, Zhang S, Chen G, Li X, Cui P, Zheng X, Hu Y. A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. J Gastrointest Oncol. 2020;11(6):1421\u201330.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"2278_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202201086","volume":"7","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zeng L, Zhu H, Wu Q, Liu R, Liang Q, Chen B, Dai H, Tang K, Liao C, et al. Ferritin nanocaged doxorubicin potentiates chemo-immunotherapy against hepatocellular carcinoma via immunogenic cell death. Small Methods. 2023;7(5): e2201086.","journal-title":"Small Methods"},{"key":"2278_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664615","volume":"11","author":"MJ Podolska","year":"2021","unstructured":"Podolska MJ, Shan X, Janko C, Boukherroub R, Gaipl US, Szunerits S, Frey B, Mu\u00f1oz LE. Graphene-induced hyperthermia (GIHT) combined with radiotherapy fosters immunogenic cell death. Front Oncol. 2021;11: 664615.","journal-title":"Front Oncol"},{"issue":"5","key":"2278_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","volume":"9","author":"K H\u00e4nggi","year":"2023","unstructured":"H\u00e4nggi K, Ruffell B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer. 2023;9(5):381\u201396.","journal-title":"Trends Cancer"},{"issue":"6","key":"2278_CR41","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.21037\/tcr-24-698","volume":"13","author":"X Zhu","year":"2024","unstructured":"Zhu X, Zhang W, Yu Z, Yang X, Li L, Chen C, Djumanazarov T, Piquemal D, Yusupbekov AA, Zheng Y. Synergistic action of gemcitabine and celecoxib in promoting the antitumor efficacy of anti-programmed death-1 monoclonal antibody by triggering immunogenic cell death. Transl Cancer Res. 2024;13(6):3031\u201345.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"2278_CR42","doi-asserted-by":"publisher","first-page":"9128","DOI":"10.1038\/s41598-024-59725-w","volume":"14","author":"Q Wei","year":"2024","unstructured":"Wei Q, Luo S, He G. Mechanism study of tyrosine phosphatase shp-1 in inhibiting hepatocellular carcinoma progression by regulating the SHP2\/GM-CSF pathway in TAMs. Sci Rep. 2024;14(1):9128.","journal-title":"Sci Rep"},{"issue":"4","key":"2278_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/imm.13853","volume":"173","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wu T, Wang Y, Luo D, Zhao Z, Sun H, Zhang M, Zhang B, Han B. Hypoxic tumour-derived exosomal miR-1290 exacerbates the suppression of CD8+ T cells by promoting M2 macrophage polarization. Immunology. 2024;173(4):672\u201388.","journal-title":"Immunology"},{"issue":"10","key":"2278_CR44","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/gutjnl-2022-327924","volume":"72","author":"Y Fu","year":"2023","unstructured":"Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, Pan H, Wang XW, He Y, Gao B. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut. 2023;72(10):1942\u201358.","journal-title":"Gut"},{"key":"2278_CR45","doi-asserted-by":"publisher","first-page":"1165243","DOI":"10.3389\/fmolb.2023.1165243","volume":"10","author":"Y Shi","year":"2023","unstructured":"Shi Y, Qiu P, Zhao K, Li X, Feng Y, Deng Z, Wang J. Identifying a novel cuproptosis-related necroptosis gene subtype-related signature for predicting the prognosis, tumor microenvironment, and immunotherapy of hepatocellular carcinoma. Front Mol Biosci. 2023;10:1165243.","journal-title":"Front Mol Biosci"},{"issue":"12","key":"2278_CR46","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/cbin.12235","volume":"48","author":"Q Chen","year":"2024","unstructured":"Chen Q, Zhang C, Meng T, Yang K, Hu Q, Tong Z, Wang X. Prediction of clinical prognosis and drug sensitivity in hepatocellular carcinoma through the combination of multiple cell death pathways. Cell Biol Int. 2024;48(12):1816\u201335.","journal-title":"Cell Biol Int"},{"issue":"1","key":"2278_CR47","doi-asserted-by":"publisher","first-page":"27529","DOI":"10.1038\/s41598-024-78911-4","volume":"14","author":"L Chen","year":"2024","unstructured":"Chen L, Hu Y, Li Y, Zhang B, Wang J, Deng M, Zhang J, Zhu W, Gu H, Zhang L. Integrated multiomics analysis identified comprehensive crosstalk between diverse programmed cell death patterns and novel molecular subtypes in hepatocellular Carcinoma. Sci Rep. 2024;14(1):27529.","journal-title":"Sci Rep"},{"issue":"5","key":"2278_CR48","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/ph16050644","volume":"16","author":"Z Cheng","year":"2023","unstructured":"Cheng Z, Huang H, Li M, Liang X, Tan Y, Chen Y. Lactylation-related gene signature effectively predicts prognosis and treatment responsiveness in hepatocellular carcinoma. Pharmaceuticals. 2023;16(5):644.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"2278_CR49","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770\u201382.","journal-title":"J Hepatol"},{"issue":"1","key":"2278_CR50","doi-asserted-by":"publisher","first-page":"11325","DOI":"10.1038\/s41598-022-15251-1","volume":"12","author":"G Zhang","year":"2022","unstructured":"Zhang G, Sun J, Zhang X. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma. Sci Rep. 2022;12(1):11325.","journal-title":"Sci Rep"},{"issue":"5","key":"2278_CR51","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s12072-022-10375-y","volume":"16","author":"C Jin","year":"2022","unstructured":"Jin C, Zhao JS, Huang XQ, Yang XZ, Niu FY, Lin JR, Ma L, Shi YX, Li XS, Jiang P, et al. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma. Hepatol Int. 2022;16(5):1220\u201333.","journal-title":"Hepatol Int"},{"issue":"1","key":"2278_CR52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1186\/s12951-024-02887-6","volume":"22","author":"H Huang","year":"2024","unstructured":"Huang H, Fu J, Peng H, He Y, Chang A, Zhang H, Hao Y, Xu X, Li S, Zhao J, et al. Co-delivery of polyphyllin II and IR780 PLGA nanoparticles induced pyroptosis combined with photothermal to enhance hepatocellular carcinoma immunotherapy. J Nanobiotechnology. 2024;22(1):647.","journal-title":"J Nanobiotechnology"},{"key":"2278_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007529","author":"R Zhang","year":"2023","unstructured":"Zhang R, Wang J, Du Y, Yu Z, Wang Y, Jiang Y, Wu Y, Le T, Li Z, Zhang G, et al. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007529.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2278_CR54","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/acsnano.0c00708","volume":"14","author":"Z Yu","year":"2020","unstructured":"Yu Z, Guo J, Hu M, Gao Y, Huang L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. ACS Nano. 2020;14(4):4816\u201328.","journal-title":"ACS Nano"},{"issue":"1","key":"2278_CR55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12951-023-02067-y","volume":"21","author":"S Zhang","year":"2023","unstructured":"Zhang S, Huang Y, Pi S, Chen H, Ye F, Wu C, Li L, Ye Q, Lin Y, Su Z. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1\/PD-L1 for residual tumors immunotherapy after RFA. J Nanobiotechnology. 2023;21(1):360.","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"2278_CR56","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/anie.201804882","volume":"58","author":"X Duan","year":"2019","unstructured":"Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed Engl. 2019;58(3):670\u201380.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"2278_CR57","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/00002371-199605000-00006","volume":"19","author":"I Haruta","year":"1996","unstructured":"Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hanyu F. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J Immunother Emphasis Tumor Immunol. 1996;19(3):218\u201323.","journal-title":"J Immunother Emphasis Tumor Immunol"},{"issue":"3","key":"2278_CR58","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.1840100318","volume":"10","author":"S Onishi","year":"1989","unstructured":"Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology. 1989;10(3):349\u201353.","journal-title":"Hepatology"},{"issue":"1","key":"2278_CR59","doi-asserted-by":"publisher","first-page":"1673129","DOI":"10.1080\/2162402X.2019.1673129","volume":"9","author":"PG Hendrickson","year":"2020","unstructured":"Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma. Oncoimmunology. 2020;9(1):1673129.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2278_CR60","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","volume":"10","author":"S Peng","year":"2022","unstructured":"Peng S, Chen S, Hu W, Mei J, Zeng X, Su T, Wang W, Chen Z, Xiao H, Zhou Q, et al. Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res. 2022;10(6):728\u201344.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2278_CR61","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773\u201396.","journal-title":"Hepatology"},{"issue":"1","key":"2278_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2278_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41416-022-01998-x","volume":"128","author":"A Ajoolabady","year":"2023","unstructured":"Ajoolabady A, Tang D, Kroemer G, Ren J. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy. Br J Cancer. 2023;128(2):190\u2013205.","journal-title":"Br J Cancer"},{"key":"2278_CR64","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.2147\/JIR.S451800","volume":"17","author":"S Li","year":"2024","unstructured":"Li S, Zhang T, Sun X, Li X. Construction of an immunogenic cell death-related gene signature and genetic subtypes for predicting prognosis, immune microenvironments, and drug sensitivity in hepatocellular carcinoma. J Inflamm Res. 2024;17:2427\u201344.","journal-title":"J Inflamm Res"},{"issue":"11","key":"2278_CR65","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41419-023-06302-0","volume":"14","author":"Z Li","year":"2023","unstructured":"Li Z, Caron de Fromentel C, Kim W, Wang WH, Sun J, Yan B, Utturkar S, Lanman NA, Elzey BD, Yeo Y, et al. RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt\/\u03b2-catenin-ferroptosis axis. Cell Death Dis. 2023;14(11):786.","journal-title":"Cell Death Dis"},{"key":"2278_CR66","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308.","journal-title":"Front Immunol"},{"issue":"8","key":"2278_CR67","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al. \u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124\u201341.","journal-title":"Cancer Discov"},{"key":"2278_CR68","doi-asserted-by":"publisher","first-page":"1156212","DOI":"10.3389\/fimmu.2023.1156212","volume":"14","author":"M Pan","year":"2023","unstructured":"Pan M, Zhao H, Jin R, Leung PSC, Shuai Z. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. Front Immunol. 2023;14:1156212.","journal-title":"Front Immunol"},{"issue":"4","key":"2278_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/CJI.0000000000000466","volume":"46","author":"S Jin","year":"2023","unstructured":"Jin S, Shang Z, Wang W, Gu C, Wei Y, Zhu Y, Yang C, Zhang T, Zhu Y, Zhu Y, et al. Immune Co-inhibitory receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in upper tract urothelial carcinomas: a large cohort study. J Immunother. 2023;46(4):154\u20139.","journal-title":"J Immunother"},{"issue":"2","key":"2278_CR70","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"1","key":"2278_CR71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.30593","volume":"70","author":"Q Wu","year":"2019","unstructured":"Wu Q, Zhou W, Yin S, Zhou Y, Chen T, Qian J, Su R, Hong L, Lu H, Zhang F, et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70(1):198\u2013214.","journal-title":"Hepatology"},{"issue":"24","key":"2278_CR72","doi-asserted-by":"publisher","first-page":"13722","DOI":"10.3390\/ijms252413722","volume":"25","author":"S Zhang","year":"2024","unstructured":"Zhang S, Chen J, Cheng F, Zheng F. The emerging role of schwann cells in the tumor immune microenvironment and its potential clinical application. Int J Mol Sci. 2024;25(24):13722.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2278_CR73","doi-asserted-by":"publisher","first-page":"24230","DOI":"10.1038\/s41598-024-75265-9","volume":"14","author":"E Heninger","year":"2024","unstructured":"Heninger E, Breneman MT, Recchia EE, Kerr SC, Dogru RE, Sharifi MN, LeBeau AM, Kosoff D. Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage reprogramming and proinflammatory T cell migration within prostate tumor models. Sci Rep. 2024;14(1):24230.","journal-title":"Sci Rep"},{"issue":"3","key":"2278_CR74","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00262-024-03930-z","volume":"74","author":"X Wang","year":"2025","unstructured":"Wang X, Yang K, Yang B, Wang R, Zhu Y, Pan T. ANKRD22 participates in the proinflammatory activities of macrophages in the colon cancer tumor microenvironment. Cancer Immunol Immunother. 2025;74(3):86.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2278_CR75","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.7150\/thno.105276","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Zhou F, Qin W, Yang Y, Li X, Liu R. Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics. 2025;15(6):2159\u201384.","journal-title":"Theranostics"},{"issue":"44","key":"2278_CR76","doi-asserted-by":"publisher","first-page":"eadp7022","DOI":"10.1126\/sciadv.adp7022","volume":"10","author":"Z Wang","year":"2024","unstructured":"Wang Z, Chen Y, Fang H, Xiao K, Wu Z, Xie X, Liu J, Chen F, He Y, Wang L, et al. Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals. Sci Adv. 2024;10(44):eadp7022.","journal-title":"Sci Adv"},{"issue":"1","key":"2278_CR77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.21037\/tcr-22-2203","volume":"12","author":"Q Ma","year":"2023","unstructured":"Ma Q, Hui Y, Huang BR, Yang BF, Li JX, Fan TT, Gao XC, Ma DY, Chen WF, Pei ZX. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases. Transl Cancer Res. 2023;12(1):46\u201364.","journal-title":"Transl Cancer Res"},{"issue":"12","key":"2278_CR78","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.21037\/tcr-23-685","volume":"12","author":"BF Yang","year":"2023","unstructured":"Yang BF, Ma Q, Hui Y, Gao XC, Ma DY, Li JX, Pei ZX, Huang BR. Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma. Transl Cancer Res. 2023;12(12):3327\u201345.","journal-title":"Transl Cancer Res"},{"key":"2278_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041623","author":"Z Liu","year":"2023","unstructured":"Liu Z, Ma H, Lai Z. The role of ferroptosis and cuproptosis in curcumin against hepatocellular carcinoma. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28041623.","journal-title":"Molecules"},{"issue":"5","key":"2278_CR80","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2019.12.014","volume":"72","author":"LQ Dong","year":"2020","unstructured":"Dong LQ, Peng LH, Ma LJ, Liu DB, Zhang S, Luo SZ, Rao JH, Zhu HW, Yang SX, Xi SJ, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72(5):896\u2013908.","journal-title":"J Hepatol"},{"key":"2278_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.831101","volume":"13","author":"L Ding","year":"2022","unstructured":"Ding L, Yu Q, Yang S, Yang WJ, Liu T, Xian JR, Tian TT, Li T, Chen W, Wang BL, et al. Comprehensive analysis of HHLA2 as a prognostic biomarker and its association with immune infiltrates in hepatocellular carcinoma. Front Immunol. 2022;13: 831101.","journal-title":"Front Immunol"},{"key":"2278_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122857","author":"E Schmitz","year":"2024","unstructured":"Schmitz E, Ridout A, Smith AL, Eiken AP, Skupa SA, Drengler EM, Singh S, Rana S, Natarajan A, El-Gamal D. Immunogenic cell death traits emitted from chronic lymphocytic leukemia cells following treatment with a novel anti-cancer agent, SpiD3. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12122857.","journal-title":"Biomedicines"},{"issue":"7","key":"2278_CR83","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.7150\/thno.71129","volume":"12","author":"L Lu","year":"2022","unstructured":"Lu L, Zhang H, Zhou Y, Lin J, Gao W, Yang T, Jin J, Zhang L, Nagle DG, Zhang W, et al. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. Theranostics. 2022;12(7):3456\u201373.","journal-title":"Theranostics"},{"issue":"23","key":"2278_CR84","first-page":"9699","volume":"14","author":"J Ma","year":"2022","unstructured":"Ma J, Kuang L, Zhao R. Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma. Aging (Albany NY). 2022;14(23):9699\u2013714.","journal-title":"Aging (Albany NY)"},{"issue":"20","key":"2278_CR85","first-page":"11389","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang L, Lei X, Yin X, Liu S. Development of an immunogenic cell death prognostic signature for predicting clinical outcome and immune infiltration characterization in stomach adenocarcinoma. Aging (Albany NY). 2023;15(20):11389\u2013411.","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"2278_CR86","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2278_CR87","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acsnano.8b05860","volume":"12","author":"T Liu","year":"2018","unstructured":"Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, Wang SB, Feng J, Zhang XZ. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano. 2018;12(12):12181\u201392.","journal-title":"ACS Nano"},{"issue":"1","key":"2278_CR88","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2278_CR89","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/02656736.2019.1569731","volume":"36","author":"J Song","year":"2019","unstructured":"Song J, Zhang F, Ji J, Chen M, Li Q, Weng Q, Gu S, Kogut MJ, Yang X. Orthotopic hepatocellular carcinoma: molecular imaging-monitored intratumoral hyperthermia-enhanced direct oncolytic virotherapy. Int J Hyperthermia. 2019;36(1):344\u201350.","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"2278_CR90","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000533650","volume":"13","author":"GK Abou-Alfa","year":"2024","unstructured":"Abou-Alfa GK, Galle PR, Chao Y, Erinjeri J, Heo J, Borad MJ, Luca A, Burke J, Pelusio A, Agathon D, et al. PHOCUS: a phase 3, randomized, open-label study of sequential treatment with pexa-vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer. 2024;13(3):248\u201364.","journal-title":"Liver Cancer"},{"issue":"5","key":"2278_CR91","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"2278_CR92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2020.01.002","volume":"474","author":"A Zhou","year":"2020","unstructured":"Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett. 2020;474:15\u201322.","journal-title":"Cancer Lett"},{"issue":"8","key":"2278_CR93","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.chom.2024.07.015","volume":"32","author":"L Chambers","year":"2024","unstructured":"Chambers L, Grencewicz D, Spakowicz D. From poo to promise: Fecal microbiota transplants support immunotherapy re-sensitization in solid tumors. Cell Host Microbe. 2024;32(8):1217\u20138.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"2278_CR94","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jgh.15715","volume":"37","author":"G Nakatsu","year":"2022","unstructured":"Nakatsu G. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma. J Gastroenterol Hepatol. 2022;37(1):34\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"15","key":"2278_CR95","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/1878-0261.13263","volume":"16","author":"Y Li","year":"2022","unstructured":"Li Y, Song Z, Han Q, Zhao H, Pan Z, Lei Z, Zhang J. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis. Mol Oncol. 2022;16(15):2861\u201380.","journal-title":"Mol Oncol"},{"issue":"24","key":"2278_CR96","doi-asserted-by":"publisher","first-page":"30671","DOI":"10.1021\/acsami.4c02740","volume":"16","author":"X Wang","year":"2024","unstructured":"Wang X, Yan B, Li H, Yuan J, Guo J, Wang S, Dai P, Liu X. Reprogrammed IDO-induced immunosuppressive microenvironment synergizes with immunogenic magnetothermodynamics for improved cancer therapy. ACS Appl Mater Interfaces. 2024;16(24):30671\u201384.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2278_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114431","volume":"161","author":"D Huang","year":"2023","unstructured":"Huang D, Xu D, Chen W, Wu R, Wen Y, Liu A, Lin L, Lin X, Wang X. Fe-MnO(2) nanosheets loading dihydroartemisinin for ferroptosis and immunotherapy. Biomed Pharmacother. 2023;161: 114431.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"2278_CR98","doi-asserted-by":"publisher","first-page":"10255","DOI":"10.1007\/s00432-023-04950-5","volume":"149","author":"T Liu","year":"2023","unstructured":"Liu T, Chen X, Peng B, Liang C, Zhang H, Wang S. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients. J Cancer Res Clin Oncol. 2023;149(12):10255\u201367.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"18","key":"2278_CR99","doi-asserted-by":"publisher","first-page":"16261","DOI":"10.1007\/s00432-023-05370-1","volume":"149","author":"G Xu","year":"2023","unstructured":"Xu G, Jiang Y, Li Y, Ge J, Xu X, Chen D, Wu J. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149(18):16261\u201377.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2278_CR100","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1021\/acsami.4c13433","volume":"17","author":"S Chen","year":"2025","unstructured":"Chen S, Sun Y, Xie Y, Liu Y, Hu H, Xie C, Xu S, Zhang Z, Zhang J, Shen Y, et al. Mitochondria-targeted icaritin nanoparticles induce immunogenic cell death in hepatocellular carcinoma. ACS Appl Mater Interfaces. 2025;17(2):2899\u2013910.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"2278_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e41380","volume":"11","author":"D Zhang","year":"2025","unstructured":"Zhang D, Lu B, Ma Q, Xu W, Zhang Q, Xiao Z, Li Y, Chen R, Wang AJ. Identification of a novel immunogenic cell death-related classifier to predict prognosis and optimize precision treatment in hepatocellular carcinoma. Heliyon. 2025;11(2): e41380.","journal-title":"Heliyon"},{"key":"2278_CR102","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.2147\/IJN.S427144","volume":"19","author":"M Wei","year":"2024","unstructured":"Wei M, Wang X, Mo Y, Kong C, Zhang M, Qiu G, Tang Z, Chen J, Wu F. Combined effects of Anti-PD-L1 and nanosonodynamic therapy on HCC immune activation in mice: an investigation. Int J Nanomed. 2024;19:7215\u201336.","journal-title":"Int J Nanomed"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02278-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:03:37Z","timestamp":1751367817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2278"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02278-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was needed because this is not a human study, but only online information was used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1208"}}